# Daiichi Sankyo Co., Ltd. clinical trials: 73 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 73 trials with Daiichi Sankyo Co., Ltd. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Daiichi Sankyo Co., Ltd.: 73 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/daiichi-sankyo-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 73
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 73, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 10, 2023 | NCT06074705 | A Study of DS-1471a In Subjects With Advanced Solid Tumors | Daiichi Sankyo Co., Ltd. | Phase 1 | Terminated | Advanced Solid Tumor | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06074705) |
| November 4, 2022 | NCT05606094 | Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or... | Daiichi Sankyo Co., Ltd. | Observational | Completed | Gastric Cancer | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05606094) |
| June 4, 2021 | NCT04914520 | Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects | Daiichi Sankyo Co., Ltd. | Phase 1 | Completed | Respiratory Syncytial Virus Infections | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04914520) |
| March 29, 2021 | NCT04821674 | Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects | Daiichi Sankyo Co., Ltd. | Phase 1/2 | Completed | Covid19 | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04821674) |
| March 26, 2021 | NCT04818398 | Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects | Daiichi Sankyo Co., Ltd. | Phase 1 | Completed | Fibrodysplasia Ossificans Progressiva | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04818398) |
| January 11, 2021 | NCT04703322 | A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan | Daiichi Sankyo Co., Ltd. | Phase 2 | Completed | Tenosynovial Giant Cell Tumor | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04703322) |
| July 28, 2020 | NCT04488822 | A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT | Daiichi Sankyo Co., Ltd. | Phase 3 | Active not recruiting | Tenosynovial Giant Cell Tumor | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04488822) |
| July 7, 2020 | NCT04459598 | A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants | Daiichi Sankyo Co., Ltd. | Phase 1 | Completed | Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04459598) |
| July 7, 2020 | NCT04459585 | A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants | Daiichi Sankyo Co., Ltd. | Early phase 1 | Completed | Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, Quizartinib | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04459585) |
| July 7, 2020 | NCT04458272 | A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma | Daiichi Sankyo Co., Ltd. | Phase 2 | Active not recruiting | WHO Grade II Glioma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04458272) |
| June 16, 2020 | NCT04433234 | Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Daiichi Sankyo Co., Ltd. | Phase 2 | Active not recruiting | Duchenne Muscular Dystrophy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04433234) |
| December 26, 2019 | NCT04211415 | Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis | Daiichi Sankyo Co., Ltd. | Phase 1 | Terminated | Atopic Dermatitis | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04211415) |
| September 25, 2019 | NCT04102150 | Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma | Daiichi Sankyo Co., Ltd. | Phase 2 | Completed | Adult T-cell Leukemia/Lymphoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04102150) |
| September 19, 2019 | NCT04094662 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral... | Daiichi Sankyo Co., Ltd. | Phase 3 | Completed | Diabetic Peripheral Neuropathic Pain | 393 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04094662) |
| April 3, 2019 | NCT03901352 | Study of Mirogabalin for Central Neuropathic Pain | Daiichi Sankyo Co., Ltd. | Phase 3 | Completed | Central Neuropathic Pain | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03901352) |
| October 29, 2018 | NCT03723681 | Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Daiichi Sankyo Co., Ltd. | Phase 1 | Completed | Acute Myeloid Leukemia (AML) | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03723681) |
| September 14, 2018 | NCT03671564 | Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Daiichi Sankyo Co., Ltd. | Phase 1 | Completed | Acute Myeloid Leukemia | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03671564) |
| July 26, 2018 | NCT03599518 | DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Daiichi Sankyo Co., Ltd. | Phase 1 | Terminated | Non Small Cell Lung Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03599518) |
| January 17, 2018 | NCT03401385 | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | Daiichi Sankyo Co., Ltd. | Phase 1 | Active not recruiting | Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer | 890 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03401385) |
| December 28, 2017 | NCT03384940 | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | Daiichi Sankyo Co., Ltd. | Phase 2 | Completed | Colorectal Neoplasm | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03384940) |
| December 26, 2017 | NCT03383692 | Study of DS-8201a for Participants With Advanced Solid Malignant Tumors | Daiichi Sankyo Co., Ltd. | Phase 1 | Completed | Neoplasm Metastasis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03383692) |
| December 8, 2017 | NCT03366428 | Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | Daiichi Sankyo Co., Ltd. | Phase 1 | Completed | Malignant Neoplasm of Breast | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03366428) |
| November 6, 2017 | NCT03329690 | DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer \[DESTINY-Gastric01\] | Daiichi Sankyo Co., Ltd. | Phase 2 | Completed | Neoplasm, Gastrointestinal | 233 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03329690) |
| June 26, 2017 | NCT03198715 | Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy | Daiichi Sankyo Co., Ltd. | Not applicable | Completed | Acute Ischemic Stroke | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03198715) |
| December 7, 2016 | NCT02984995 | Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation | Daiichi Sankyo Co., Ltd. | Phase 2 | Completed | Leukemia, Myeloid, Acute | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02984995) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 22 |
| Phase 1/2 | 3 |
| Phase 2 | 17 |
| Phase 3 | 19 |
| Phase 4 | 1 |
| Not applicable | 7 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 64 |
| Active not recruiting | 5 |
| Terminated | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 13 |
| Diabetes Mellitus, Type 2 | 7 |
| Venous Thromboembolism | 6 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Hypertension | 5 |
| Venous Thrombosis | 5 |
| Leukemia, Myeloid, Acute | 5 |
| Essential Hypertension | 4 |
| Atrial Fibrillation | 4 |
| Thromboembolism | 4 |
| Thrombosis | 4 |
| Renal Insufficiency | 4 |
| Diabetic Nephropathies | 3 |
| Stomach Neoplasms | 2 |
| Respiratory Tract Neoplasms | 2 |
| Giant Cell Tumor of Tendon Sheath | 2 |
| Embolism | 2 |
| Adenocarcinoma | 2 |
| Colorectal Neoplasms | 2 |
| Neuralgia, Postherpetic | 2 |
| Muscular Dystrophy, Duchenne | 2 |
| Embolism and Thrombosis | 2 |
| Breast Neoplasms | 2 |
| Small Cell Lung Carcinoma | 1 |
| Uterine Cervical Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fertility clinics in the United States](https://specstream.ai/data/businesses/fertility-clinics/united-states)
- [Automotive companies in the United States](https://specstream.ai/data/businesses/automotive-companies/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [Gluten free restaurants in the United States](https://specstream.ai/data/businesses/gluten-free-restaurants/united-states)
- [Banks and credit unions in the United States](https://specstream.ai/data/businesses/banks-and-credit-unions/united-states)
- [Rubber and plastics manufacturers in the United States](https://specstream.ai/data/businesses/rubber-and-plastics-manufacturers/united-states)
